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INTRODUCTION
Over the last decade, performance- based 
financing (PBF) has gained momentum as a 
health financing innovation, which combines 
linking healthcare payments to performance 
with increased provider autonomy and super-
vision.1 2 The combination of these elements is 
expected to boost supply- side efforts towards 
increasing quantity and quality of service 
provision, triggering a demand- side response 
towards improved service utilisation.1 3 4
A recent paper by Paul et al has critically 
questioned the widespread introduction of 
PBF in light of the limited available evidence 
on its effectiveness.5 The response to this 
paper has been varied, with authors advancing 
arguments for and against PBF. Some African 
PBF implementers have claimed that PBF is 
an evolving strategy with potential benefits 
on health systems despite its existing chal-
lenges.6 Others have drawn attention to the 
unintended consequences of PBF7 or to the 
need to assess the economic value of such an 
approach.8 Beyond their diverse arguments, 
however, most authors have concurred with 
Paul et al5 on the limited scope of currently 
available evidence and have postulated the 
need to better assess how PBF works under 
different contextual constraints within and 
across settings.9 10
Our commentary positions itself against 
this background, acknowledges the limited 
scope of current evidence on PBF, and explic-
itly argues in favour of devoting more effort 
to unravel heterogeneity across and within 
settings. Our argument is based on the recog-
nition that by virtue of how impact evalua-
tions are designed, the focus has been on 
the average effect, which masks important 
heterogeneity across settings, providers and 
users.11–13 To date, only a handful of studies 
have assessed heterogeneity of PBF effects 
across population subgroups4 14 15 or across 
health providers.16–18 Similarly, little atten-
tion has been devoted to understanding 
which factors can explain heterogeneity 
in the response to PBF or why PBF stimu-
lates changes in some instances, but not in 
others.3 4 10
In light of the above, we call for more 
systematic analyses of heterogeneity, defined 
in relation to both the need to report differ-
ential effects and the need to understand what 
drives or explains such differential effects 
within and across settings. We first define and 
outline potential sources of heterogeneity 
and then offer initial guidance on how to 
measure and understand heterogeneity.
Potential sources of heterogeneity in PBF
PBF interventions are not uniformly designed 
or implemented across settings. Variations in 
Summary box
 ► Performance- based financing (PBF) is widely im-
plemented despite limited available evidence on its 
effectiveness.
 ► There is a need to assess how PBF works in differ-
ent contexts within and across settings in order to 
inform country- level decisions as to whether PBF 
may be a suitable health financing option and how 
it should be shaped to suit different contexts within 
a country.
 ► This commentary intends to inspire research look-
ing beyond average programme effects into under-
standing heterogeneity in PBF programmes and their 
effects.
 ► As a starting point, we propose to document and 
analyse all potential sources of heterogeneity in PBF.
 ► We further provide initial guidance to conduct sys-
tematic analyses of heterogeneity of PBF by measur-
ing and understanding differential effects and what 
drives or explains them.
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design, implementation models, and settings, inevitably 
lead to substantial heterogeneity in PBF programmes 
and eventually effects.3 4 19 However, publications rarely 
detail these variations, inevitably omitting underlying 
programme heterogeneity and hence nurturing a false 
view of PBF as a monolithic intervention. Furthermore, 
within a single setting, PBF addresses organisational units 
and actors whose intrinsic diversity represents an addi-
tional source of heterogeneity for PBF implementation 
and effects. Hereafter, we address three key sources of 
heterogeneity.
Design features of PBF
First, we highlight the need to account for PBF design 
features as part of a researcher’s core engagement into 
unravelling heterogeneity. PBF programmes vary in many 
aspects, all worth reporting given their potential to shape 
responses to the programme: what services are incenti-
vised and how (restricted vs extensive service package; 
case based vs target payments); who is eligible for incen-
tives (individual providers vs health facilities vs both); the 
level of autonomy granted to providers; frequency and 
content of supervision and verification visits.19 It is also 
relevant to describe how performance is measured and 
along which dimensions and to consider whether PBF is 
implemented on its own or in conjunction with demand- 
side interventions.
Contextual and structural factors
Relevant contextual characteristics can be identified at 
international, national, local and institutional level, as 
well as at the level of the individual actors.3 At national 
level, countries differ in terms of health system setup (eg, 
financing mechanisms, resource availability) and pre- PBF 
performance. In some instances, heterogeneity arises as 
PBF is implemented alongside another health financing 
reform (eg, health insurance, user fee removal) or in 
a fragile and conflict- affected region.9 At subnational 
level, PBF effects may for instance vary substantially 
across districts and facilities, levels of care or public and 
private facilities. This heterogeneity may be due to vari-
ation in: resource availability; complexity and scope of 
service provision; health staff’s availability, competence 
and motivation; facility remoteness and spread of catch-
ment populations; and pre- PBF performance in regard 
to service coverage and quality.15 17 18
Implementation processes and progress
Variations in implementation fidelity and/or implemen-
tation failures can also explain heterogeneity both within 
and across PBF programmes and settings.3 Process anal-
yses are useful to detect differences in implementation 
fidelity across settings as well as within single programmes. 
Researchers are advised to document losses in imple-
mentation fidelity at different levels (from programme 
orientation to implementing activities to timeliness of 
PBF payments) as an important potential source of heter-
ogeneity.
How to measure heterogeneity in PBF
Having acknowledged diverse sources of heterogeneity, 
we provide some initial practical guidance on how to look 
beyond average programme effects using both quantita-
tive and qualitative methods, the former being oriented 
at measurement and the latter at in- depth understanding. 
The propositions below can be applied to assess heter-
ogeneity across a wide range of PBF- related outcomes, 
including providers’ motivation and performance, health 
service utilisation and quality of service provision.
Capture health systems factors, community and population 
characteristics
One’s capacity to assess heterogeneity begins with having 
access to comprehensive information on the characteris-
tics of both healthcare providers implementing PBF and 
target communities. Similarly, information on contextual 
elements, implementation models and implementation 
fidelity at different levels of the health system is needed. 
Depending on the specific focus of one’s analysis, this 
information can be captured quantitatively through use 
of routine data sources (eg, Health Management Infor-
mation Systems), facility- based and population- based 
surveys, or qualitatively through means of document 
reviews, observations and interview methods.
Identify relevant subgroups to analyse heterogeneity of PBF effects
The identification of potential sources of heteroge-
neity can be done through data disaggregation. This 
entails categorising data by key actors (eg, different 
sets of providers/users), by setting (eg, rural–urban, 
different districts), by different implementation models 
and different levels of implementation fidelity, or by 
any other conceptually pertinent factor, including, for 
example, facilities baseline performance levels or mana-
gerial capacity. Assessing heterogeneity quantitatively or 
qualitatively effectively entails having sufficient informa-
tion to allow for subgroup analysis (comparison between 
groups) in relation to any of the above- mentioned 
categories. This of course relies on having engaged in 
comprehensive data collection efforts from the onset of 
the study and on defining relevant subgroups in relation 
to relevant sources of heterogeneity, the specific research 
questions being addressed, the study conceptual model 
or the intervention broader contextual elements.
Select an appropriate analytical approach
When assessing heterogeneity quantitatively, the choice 
for an appropriate quantitative analytical approach 
largely relies on the typology of the data available—
time series data, panel data or repeated cross- sectional 
data—as well as on the specific research question being 
addressed. Within the PBF literature in low- income and 
middle- income countries, only a few studies to date have 
explicitly used interactions terms and/or stratified anal-
ysis to assess differential impacts across subgroups of 
providers and users.14–17 Some authors have proposed 
additional analytical options to estimate heterogeneity 
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of programme effects. For instance, some authors have 
used quantile- specific treatment effects,11 13 while others 
have used hierarchical linear models on propensity score 
strata to estimate the distributional impact of policies.20
Assessing heterogeneity qualitatively means assessing 
how different constituencies within and across settings 
define and experience PBF in light of broader contex-
tual and implementation- specific elements. Thematic 
descriptive qualitative analysis has largely dominated this 
body of literature.18 We note that with a few exceptions, 
quantitative and qualitative analytical approaches have to 
date rarely been merged into a single research effort to 
explore specifically heterogeneity in PBF effects.
CONCLUSION
With this brief commentary, we wish to inspire the 
research and policy community to look beyond average 
programme effects, devoting more attention towards 
measuring and understanding heterogeneity in PBF 
programmes and their effects. Understanding heteroge-
neity represents an essential step towards establishing the 
needed evidence base to inform country- level decisions 
as to whether PBF may be a suitable health financing 
option for a given setting. In addition, understanding 
heterogeneity and its sources also represents the initial 
step towards adjusting design and implementation to 
take into account the different actors and realities that 
may co- exist within a single setting.
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